RxDoctor Payments Data

Frank Evans, DO

Family Medicine · Stillwater, OKNPI 1639158355

Payments from drug & device makers

$6,928in general payments, 2019–2025

Across 450 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$701
  • Lilly USA, LLC$641
  • Merck$465
  • Pfizer$353
  • Supernus Pharmaceuticals, Inc.$351
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$6,86899%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,928 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$73,856
Medicare patients
248
Services billed
5,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$66,345
JardianceEmpagliflozin49$49,273
MounjaroTirzepatide24$33,185
JanumetSitagliptin Phos/Metformin Hcl28$19,199
EliquisApixaban27$16,723
XareltoRivaroxaban15$16,420
MyrbetriqMirabegron20$12,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,789
InvokanaCanagliflozin12$6,989
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,051
Levothyroxine Sodium300$2,788
Atorvastatin Calcium228$2,695
Pregabalin27$1,613
Omeprazole92$1,555
PaxlovidNirmatrelvir/Ritonavir11$1,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$278$66,34554 claims
Boehringer IngelheimJardiance$264$49,27349 claims
Lilly USA, LLCMounjaro$641$33,18524 claims
Johnson & JohnsonXarelto, Invokana$271$23,40927 claims
MerckJanumet$465$19,19928 claims
PfizerEliquis, Paxlovid$353$18,15238 claims
Astellas Pharma US IncMyrbetriq$16$12,82420 claims
AstraZenecaBreztri Aerosphere$701$10,78913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →